What is Wright Medical Group Earnings Yield (Joel Greenblatt) %?
Wright Medical Group's Enterprise Value for the quarter that ended in Jun. 2015 was €0.0 Mil.
Wright Medical Group's EBIT for the trailing twelve months (TTM) ended in Jun. 2015 was €-99.1 Mil. Wright Medical Group's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2015 was 0.00%.
The historical rank and industry rank for Wright Medical Group's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
FRA:WM3'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -9.1 Med: 3.1 Max: 7.7
Current: -9.1
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Wright Medical Group was 7.70%. The lowest was -9.10%. And the median was 3.10%.
FRA:WM3's Earnings Yield (Joel Greenblatt) % is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 0.23
vs FRA:WM3: -9.10
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Wright Medical Group's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2015 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Wright Medical Group Earnings Yield (Joel Greenblatt) % Historical Data
The historical data trend for Wright Medical Group's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Wright Medical Group Earnings Yield (Joel Greenblatt) % Chart
Competitive Comparison of Wright Medical Group's Earnings Yield (Joel Greenblatt) %
For the Medical Devices subindustry, Wright Medical Group's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wright Medical Group's Earnings Yield (Joel Greenblatt) % Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Wright Medical Group's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Wright Medical Group's Earnings Yield (Joel Greenblatt) % falls into.
Wright Medical Group Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Wright Medical Groups Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2014 is calculated as
Wright Medical Group's EBIT for the trailing twelve months (TTM) ended in Jun. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was €-99.1 Mil.
Wright Medical Group (FRA:WM3) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Wright Medical Group Earnings Yield (Joel Greenblatt) % Related Terms
Thank you for viewing the detailed overview of Wright Medical Group's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.
Wright Medical Group (FRA:WM3) Business Description
Wright Medical Group Inc, through Wright Medical Technology, Inc. and other operating subsidiaries, is a specialty orthopaedic company, that provides extremity and biologic solutions that enable clinicians to alleviate pain and restore their patients' lifestyles. The Company provides surgical solutions for the foot and ankle market and markets its products in over 60 countries. Its business includes products that are used in foot and ankle repair, upper extremity products, and biologics products, which are used to replace damaged or diseased bone, to stimulate bone growth and to provide other biological solutions for surgeons and their patients. Extremity hardware includes implants and other devices to replace or reconstruct injured or diseased joints and bones of the foot, ankle, hand, wrist, fingers, toes, elbow and shoulder, which it generally refer to as either foot and ankle or upper extremity products. The Company's manufacturing and warehousing operations are located in Arlington, Tennessee. Outside the U.S., The Company has distribution and administrative facilities in Amsterdam, the Netherlands, and sales and distribution offices in Canada, Australia, and Europe. The Company operates its continuing operations as one reportable segment and offer products in extremity reconstruction and biologics. The Company's products include CHARLOTTE, CLAW II, DARCO, EVOLVE, MICRONAIL, GRAFTJACKET, OSTEOSET. Its competitors include major companies in the orthopaedic and biologics industries, as well as academic institutions and other public and private research organizations that continue to conduct research, seek patent protection and establish arrangements for commercializing products. The Company's products are strictly regulated by the FDA under the Food, Drug, and Cosmetic Act. Some of its products are also regulated by state agencies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:WM3 has been successfully added to your 